Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/30705
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 謝銘鈞 | |
dc.contributor.author | Hao-Yang Sun | en |
dc.contributor.author | 孫浩陽 | zh_TW |
dc.date.accessioned | 2021-06-13T02:12:58Z | - |
dc.date.available | 2007-06-15 | |
dc.date.copyright | 2007-06-15 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-06-07 | |
dc.identifier.citation | [1]. P. Harrod-Kim; Tumor ablation with photodynamic therapy: introduction to mechanism and clinical applications. J Vasc Interv Radiol. 17 (2006) 1441–8.
[2]. H. Kato; Photodynamic therapy for lung cancer–a review of 19 years’ experience. J. Photochem. Photobiol. B 42 (1998) 96–9. [3]. D. Ost; Photodynamic therapy in lung cancer. A review, Methods Mol. Med. 75 (2003) 507–26. [4]. R.L. Prosst, H.C. Wolfsen, J. Gahlen; Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy 35 (2003) 1059–68. [5]. F. Guillemin, X. Feintrenie, D. Lignon; Photodynamic therapy of bronchogenic cancer. Rev. Pneumol. Clin. 48 (1992) 111–4. [6]. J. Moan, K. Berg; The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol. 53 (1991) 549–53. [7]. T.J. Dougherty, C.J. Gomer, B.W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan, Q. Peng; Photodynamic therapy. J. Natl. Cancer Inst. 90 (1998) 889–905. [8]. Kessel D; Correlation between subcellular localization and photodynamic efficacy. J Porphyrins Phthalocyanines 8 (2004) 1009–14. [9]. M.R. Detty, S.L. Gibson, S.J. Wagner; Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 47 (2004) 3897–915. [10]. Vicente MG; Porphyrin-based sensitizers in the detection and treatment of cancer: recent progress. Curr. Med. Chem. 1 (2001) 175–94. [11]. S.K. Pushpan, S. Venkatraman, V.G. Anand, Sankar J, D. Parmeswaran, S. Ganesan, T.K. Chandrashekar; Porphyrins in photodynamic therapy-a search for ideal photosensitizers. Curr. Med. Chem. 2 (2002) 187–207. [12]. S.L. Gibson, J.J. Havens, M.L. Nguyen, R. Hilf; Delta-aminolaevulinic acid-induced photodynamic therapy inhibits protoporphyrin IX biosynthesis and reduces subsequent treatment efficacy in vitro. Brit. J. Cancer 80 (1999) 998–1004. [13]. T. Mosmann; Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55–63. [14]. T. Decker, M.L. Lohmann-Matthes; A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol. Methods 115 (1988) 61–9. [15]. C. Korzeniewski, D.M. Callewaert; An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 64 (1983) 313–20. [16]. S. Hammerschmidt, H. Kuhn, T. Grasenack, C. Gessner, H. Wirtz; Apoptosis and necrosis induced by cyclic mechanical stretching in alveolar type II cells. Am. J. Respir. Cell Mol. Biol. 30 (2004) 396–402. [17]. L. Zamai, E. Falcieri, G. Zauli, A. Cataldi, M. Vitale; Optimal detection of apoptosis by flow cytometry depends on cell morphology. Cytometry 14 (1993) 891–97. [18]. Y. Youngjae, L.S. Gibson, M. R. Detty; Phototoxicity of a core-modified porphyrin and induction of apoptosis. Journal of Photochemistry and Photobiology B 85 (2006) 155–62. [19]. V.A. Fadok, D.R. Voelker, P.A. Campbell, J.J. Cohen, D.L. Bratton, P.M. Henson; Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148 (1992) 2207–16. [20]. P. Thiagarajan, J.F. Tait; Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J. Biol. Chem. 256 (1990) 17420–3. [21]. G. Koopman, C.P. Reutelingsperger, G.A. Kuijten, R.M. Keehnen, S.T. Pals, M.H. van Oers; Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 85 (1994) 1415–20. [22]. Y. Gavrieli, Y. Sherman, S.A. Ben-Sasson; Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119 (1992) 493–501. [23]. T. Tsai, Ruey-Long Hong, Jui-Chang Tsai, Pei-Jen Lou, I-Fang Ling, Chin-Tin Chen; Effect of 5-aminolevulinic acid-mediated photodynamic therapy on MCF-7 and MCF-7/ADR cells. Lasers in Surgery and Medicine 34 (2004) 62–72. [24]. V.C. Leite, R.F. Santos, L.C. Chen, L.A. Guillo; Psoralen derivatives and long wave ultraviolet irradiation are active in vitro against human melanoma cell line. Journal of Photochemistry and Photobiology B: Biology 76 (2004) 49–53. [25]. I. Mickuviene, V. Kirveliene, B. Juodka; Experimental survey of non-clonogenic viability assays for adherent cells in vitro. Toxicology in Vitro 18 (2004) 639–648. [26]. G. Spagnuolo, V. D’Anto, C. Cosentino, G. Schmalz, H. Schweikl, S. Rengo; Effect of N-acetyl-L-cysteine on ROS production and cell death caused by HEMA in human primary gingival fibroblasts. Biomaterials 27 (2006) 1803–9. [27]. J. Michie, J. Akudugu, A. Binder, C.E. Van Rensburg, L. Bohm; Flow cytometric evaluation of apoptosis and cell viability as a criterion of anti-tumour drug toxicity. Anticancer Res. 23 (2003) 2675–9. [28]. C. McNeill-Blue, B.A. Wetmore, J.F. Sanchez, W.J. Freed, B.A. Merrick; Apoptosis mediated by p53 in rat neural AF5 cells following treatment with hydrogen peroxide and staurosporine. Brain Research 1112 (2006) 1–15. [29]. M. Hayashi, K. Uehara, Y. Ichikawa, S. Arai, E. Isogai, T. Okui;Higher sensitivity in induction of apoptosis in fibroblast cell lines derived from LEC strain rats to UV-irradiation. J.Vet.Med.Sci. 60 (1998) 207–12. [30]. S. Marchal, A. Fadloun, E. Maugain, Marie-Ange D’Hallewin, F. Guillemin, L. Bezdetnaya; Necrotic and apoptotic features of cell death in response to Foscan photosensitization of HT29 monolayer and multicell spheroids. Biochemical Pharmacology 69 (2005) 1167–76. [31]. A.M.R. Fisher, A. Ferrario, N. Rucker, S. Zhang, C.J. Gomer; Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function. Cancer Research 59 (1999) 331–35. [32]. Y. Tian, W. Leung, K. Yue, N. Mak; Cell death induced by MPPa–PDT in prostate carcinoma in vitro and in vivo. Biochemical and Biophysical Research Communications 348 (2006) 413–20. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/30705 | - |
dc.description.abstract | 目的: 以5,10-biaminophenyl-15,20-bipyridinyl porphyrin (BABPP)對子宮頸癌細胞光敏化後, 探討以光動力治療造成之細胞死亡, 其壞死與凋亡的特徵.
材料與方法:我們用3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 分析與乳酸脫氫酶(LDH)滲漏分析決定光動力治療後的細胞毒性. 流式細胞儀分析用於測定細胞週期及細胞壞死與凋亡的分布比例.結果: MTT分析顯示BABPP在黑暗中具有極低的細胞毒性.此外, 細胞存活率隨藥物濃度與照光劑量之提高而逐漸降低. 細胞存活率在照光後隨時間推移而漸次下降, 與LDH滲漏分析的結果有良好的對應關係.藉由流式細胞儀的分析, 我們發現在光動力治療後出現的壞死細胞在某個時間點之後會漸漸減少, 最後凋亡會逐漸變成細胞死亡的主要方式. 以碘化丙啶(PI)對細胞染色後作流式細胞儀分析則顯示亞G1峰在光動力治療後3小時就出現, 且隨時間推移而更趨顯著; 同時G2/M期的比例則逐步縮小. 結論: 在照光後的時間過程裡, 由凋亡或壞死細胞特徵之表現與LDH滲漏分析的結果可以辨識出兩種細胞破壞的機制. 以BABPP為光感藥物之光動力治療, 其產生之細胞死亡係透過凋亡與壞死兩種方式進行. 最後, 細胞凋亡的程度隨照光後時間流逝而漸次上揚, 且依照光劑量與藥物濃度而定. BABPP是一種值得進一步探索之有潛力的新型光感藥物. | zh_TW |
dc.description.abstract | Purpose: To investigate the necrotic and apoptotic features of cell death in response to 5,10-biaminophenyl-15,20-bipyridinyl porphyrin (BABPP) photosensitization of HeLa cells.
Material and Methods: We used 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and lactate dehydrogenase (LDH) leakage assay to determine cytotoxicity in HeLa cells after photodynamic therapy (PDT). Flow cytometric analysis was used to evaluate the cell cycle and the distributive ratio of apoptotic versus necrotic cells. Results: The MTT assay revealed low cytotoxicity in the dark; further, cell viability declined in a dose-dependent manner for drugs and illumination. The survival rate gradually decreased during the postirradiation period, and it correlated well with the results of the LDH leakage assay. By flow cytometric analysis, we observed that the necrotic cells gradually disappeared at some point after PDT, and eventually, apoptosis became the main pattern of cell death. The flow cytometric analysis of propidium iodide (PI)-stained HeLa cells revealed a subG1 peak 3 hr after PDT that progressively became more prominent during the postexposure time; simultaneously, the proportion of the G2/M phase slowly diminished. Conclusion: There are 2 mechanisms of cellular destruction identified from the time course of LDH leakage and from the manifestation of markers of apoptosis or necrosis. BABPP-based PDT-mediated cell death can advance through both necrotic as well as apoptotic pathways. Finally, the extent of apoptosis was time-related and displayed drug and light dose-dependent characteristics. Thus, BABPP is a potential photosensitizer worthy of further investigation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T02:12:58Z (GMT). No. of bitstreams: 1 ntu-96-R93548046-1.pdf: 513140 bytes, checksum: cb03d7ff514b26429594f63766018802 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | Content
中文摘要……………………………………………………………………………… 1 ABSTRACT ………………………………………………………………………… 2 INTRODUCTION…………………………………………………………………… 3 MATERIAL AND METHODS……………………………………………………… 5 Cell line & culture…………………………………………………………………….. 5 Chemicals and reagents……………………………………………………………….. 5 Light source…………………………………………………………………………… 5 Cytotoxicity assay……………………………………………………………………... 5 Lactate dehydrogenase (LDH) leakage assay…………………………………………..6 Determination of cell death…………………………………………………………….6 Cell cycle analysis by flow cytometry………………………………………………… 7 RESULTS……………………………………………………………………………… 8 Drug and illumination dose dependency of phototoxicity in HeLa cells……………… 8 Drug and illumination dose dependency of apoptotic rate in HeLa cells………………8 Alteration of the cell cycle during the postirradiation period in PDT-treated HeLa cells ………………………………………………………………………………………… 9 DISCUSSION………………………………………………………………………...10 FIGURES………………………………………………………………………………12 Scheme 1………………………………………………………………………………12 Fig 1A…………………………………………………………………………………12 Fig 1B…………………………………………………………………………………12 Fig 1C…………………………………………………………………………………12 Fig 1D…………………………………………………………………………………12 Fig 1E…………………………………………………………………………………13 Fig 1F…………………………………………………………………………………13 Fig 2A…………………………………………………………………………………14 Fig 2B…………………………………………………………………………………14 Fig 2C…………………………………………………………………………………15 Fig 2D…………………………………………………………………………………15 Fig 2E…………………………………………………………………………………16 Fig 2F…………………………………………………………………………………16 Fig 2G…………………………………………………………………………………16 Fig 2H…………………………………………………………………………………16 Fig 3A…………………………………………………………………………………17 Fig 3B…………………………………………………………………………………17 Fig 3C…………………………………………………………………………………18 Fig 3D…………………………………………………………………………………18 CONCLUSION………………………………………………………………………..20 REFERENCES………………………………………………………………………..21 APPENDIX…………………………………………………………………………….24 | |
dc.language.iso | en | |
dc.title | 以5,10-biaminophenyl-15,20-bipyridinyl porphyrin為光感藥物作光動力治療誘導子宮頸癌細胞死亡之模式探討 | zh_TW |
dc.title | The mode of cell death induced by 5,10-biaminophenyl-15,20-bipyridinyl porphyrin- based photodynamic therapy in HeLa cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 婁培人,楊台鴻,賴秉杉 | |
dc.subject.keyword | 光感藥物,光動力治療,凋亡,壞死,細胞週期, | zh_TW |
dc.subject.keyword | photosensitizer,photodynamic therapy,apoptosis,necrosis,cell cycle, | en |
dc.relation.page | 24 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-06-07 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
Appears in Collections: | 醫學工程學研究所 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-96-1.pdf Restricted Access | 501.11 kB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.